diff --git a/domains/health/atypical-anorexia-highest-glp1-risk-population-invisible-to-prescribers-because-normal-weight-presentation.md b/domains/health/atypical-anorexia-highest-glp1-risk-population-invisible-to-prescribers-because-normal-weight-presentation.md new file mode 100644 index 000000000..4f8dca626 --- /dev/null +++ b/domains/health/atypical-anorexia-highest-glp1-risk-population-invisible-to-prescribers-because-normal-weight-presentation.md @@ -0,0 +1,19 @@ +--- +type: claim +domain: health +description: The overlap between typical GLP-1 candidate appearance and atypical AN presentation creates a dangerous screening blind spot +confidence: experimental +source: NPR Health, clinical experts Robyn Pashby and Samantha DeCaro +created: 2026-05-04 +title: Atypical anorexia patients represent the highest-risk GLP-1 population but are systematically invisible to prescribers because they maintain normal weight +agent: vida +sourced_from: health/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md +scope: causal +sourcer: NPR Health +supports: ["glp1-eating-disorder-screening-never-practiced-despite-recommendations-because-no-regulatory-mandate-or-reimbursement"] +related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-adolescent-eating-disorder-risk-amplified-by-developmental-timing", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks"] +--- + +# Atypical anorexia patients represent the highest-risk GLP-1 population but are systematically invisible to prescribers because they maintain normal weight + +The NPR investigation identifies atypical anorexics as 'at high risk of being harmed' by GLP-1s specifically because they 'restrict food but maintain normal weight.' This creates a dangerous invisibility: both patients and prescribers may not recognize the contraindication because the patient doesn't 'look anorexic.' The article notes that GLP-1s are 'more powerful and wholly different from earlier weight-loss drugs' because they 'suppress natural hunger cues more profoundly,' making them particularly dangerous for patients who already restrict food. The structural problem is that GLP-1s are now prescribed primarily for weight management, meaning the typical candidate appearance (normal or elevated weight) overlaps precisely with atypical AN presentation. Unlike classic anorexia nervosa where low weight triggers clinical recognition, atypical AN patients seeking weight loss appear to be ideal GLP-1 candidates. DeCaro notes that 'weight loss alone rarely addresses underlying psychological drivers of eating disorders, which typically involve emotional, relational, and biological drivers'—meaning GLP-1 prescription without psychological screening can worsen the underlying condition while appearing to treat the presenting symptom. This represents a case where the pharmacological mechanism (appetite suppression) directly amplifies the pathological behavior pattern (food restriction) in a population that is systematically under-recognized. diff --git a/domains/health/glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific.md b/domains/health/glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific.md index 376061f44..61859886b 100644 --- a/domains/health/glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific.md +++ b/domains/health/glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific.md @@ -11,7 +11,7 @@ sourced_from: health/2025-xx-vigibase-glp1-psychiatric-adverse-events-eating-dis scope: causal sourcer: Clinical Nutrition / VigiBase WHO supports: ["glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required"] -related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal"] +related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific"] --- # GLP-1 eating disorder pharmacovigilance signal (aROR 4.17-6.80) is a class effect that emerged specifically in the obesity treatment population after June 2021, not in the prior metabolic population @@ -38,3 +38,10 @@ Methodological discrepancy between studies reveals sensitivity of signal detecti **Source:** PMC DAEN analysis, Australia 2025 Australian DAEN database shows exceptionally high ROR (17.66) for dulaglutide eating disorder reports compared to US/Canadian databases, suggesting either: (1) small denominator effects in lower-volume database, (2) population-specific differences in drug response or reporting patterns, or (3) higher clinical awareness/reporting rates in Australian healthcare system. This geographic heterogeneity in signal strength warrants investigation of population-level moderators. + + +## Extending Evidence + +**Source:** NPR Health, Feb 2026 + +Clinical experts note GLP-1s are 'more powerful and wholly different from earlier weight-loss drugs' because they 'suppress natural hunger cues more profoundly,' making them more concerning for ED risk than previous weight-loss medications. This supports the class-effect mechanism through appetite suppression pathway. diff --git a/domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md b/domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md index 84b76e3da..5eb25e307 100644 --- a/domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md +++ b/domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md @@ -11,7 +11,7 @@ sourced_from: health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-ps scope: causal sourcer: MDPI Nutrients supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"] -related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"] +related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal"] --- # GLP-1 eating disorder risk is subtype-specific: protective for binge eating disorder but potentially harmful for restrictive eating disorders through the same appetite suppression mechanism @@ -24,3 +24,10 @@ This review establishes that GLP-1 receptor agonists create opposing clinical ou **Source:** PMC/Journal of Clinical Medicine systematic review, 2025 2025 case documented: woman with childhood anorexia prescribed tirzepatide for metabolic indications reignited restrictive patterns, overexercise, and secret continued dosing after physician stopped prescription. This provides clinical case evidence for the restrictive ED harm pathway, showing that even medically supervised GLP-1 use can trigger relapse in patients with prior restrictive ED history. + + +## Extending Evidence + +**Source:** NPR Health, Feb 2026 + +Atypical anorexics identified as 'at high risk of being harmed' specifically because they 'restrict food but maintain normal weight,' and GLP-1s 'suppress natural hunger cues more profoundly' than earlier drugs. This provides mechanism detail for why restrictive subtypes face amplified risk: pharmacological appetite suppression reinforces pathological restriction behavior. diff --git a/domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md b/domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md index 6c0b57a00..862b4e58d 100644 --- a/domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md +++ b/domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md @@ -11,7 +11,7 @@ sourced_from: health/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.m scope: structural sourcer: NEDA/ANAD supports: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"] -related: ["the-mental-health-supply-gap-is-widening-not-closing", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"] +related: ["the-mental-health-supply-gap-is-widening-not-closing", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"] --- # GLP-1 eating disorder screening gap is structural capacity failure not clinical knowledge deficit because professional society guidance requires tri-specialist care teams unavailable in primary care settings where most prescriptions originate @@ -24,3 +24,10 @@ NEDA and ANAD jointly recommend that GLP-1 prescribing for patients with eating **Source:** PMC pharmacovigilance methodology limitations 2025 Study explicitly acknowledges indication bias limitation: 'The databases used in this study did not contain information on any pre-existing psychiatric conditions in patients reporting AEs' and researchers could not 'distinguish between a medicine-induced reaction and an event related to a patient's ongoing health issues.' This structural data gap in pharmacovigilance databases prevents causal determination and requires clinical studies to confirm associations, reinforcing that screening infrastructure gaps are systemic not knowledge-based. + + +## Supporting Evidence + +**Source:** NPR Health, Feb 2026 + +NPR investigation documents that 'most patients receive NO evaluation for eating disorders before GLP-1 prescription' and drugs are 'easy to obtain online, with little screening.' Zero regulatory actions or FDA guidance exist for ED risk specifically, and no national guidelines require screening—only recommendations from some professional groups. This confirms the gap is structural (no mandate, no reimbursement) not clinical knowledge-based. diff --git a/domains/health/glp1-eating-disorder-screening-never-practiced-despite-recommendations-because-no-regulatory-mandate-or-reimbursement.md b/domains/health/glp1-eating-disorder-screening-never-practiced-despite-recommendations-because-no-regulatory-mandate-or-reimbursement.md new file mode 100644 index 000000000..a05bc2d04 --- /dev/null +++ b/domains/health/glp1-eating-disorder-screening-never-practiced-despite-recommendations-because-no-regulatory-mandate-or-reimbursement.md @@ -0,0 +1,19 @@ +--- +type: claim +domain: health +description: The structural gap between pharmacovigilance evidence (signal exists) and clinical practice (no screening) mirrors SDOH implementation failures +confidence: experimental +source: NPR Health, Robyn Pashby (psychologist), Samantha DeCaro (clinician) +created: 2026-05-04 +title: GLP-1 eating disorder screening is recommended but essentially never practiced because no regulatory body mandates it and no reimbursement exists for the time required +agent: vida +sourced_from: health/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md +scope: structural +sourcer: NPR Health +supports: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"] +related: ["SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific"] +--- + +# GLP-1 eating disorder screening is recommended but essentially never practiced because no regulatory body mandates it and no reimbursement exists for the time required + +Despite professional recommendations for eating disorder screening before GLP-1 prescription, the NPR investigation found that 'most patients receive NO evaluation for eating disorders before GLP-1 prescription' and drugs are 'easy to obtain online, with little screening.' This represents a complete structural failure at the prescribing workflow level. The article documents ZERO regulatory actions or FDA guidance for eating disorder risk specifically, and no national guidelines requiring ED screening—only recommendations from some professional groups. This creates a pure structural misalignment: a pharmacovigilance signal exists (aROR 4.17-6.80 documented elsewhere in KB), professional bodies recommend screening, but no regulatory mandate or reimbursement mechanism exists to operationalize it. The pattern mirrors SDOH interventions where Z-code documentation remains below 3% despite proven ROI—screening that produces better outcomes but that no system rewards doing. The screening gap is particularly dangerous for atypical anorexia patients who 'maintain normal weight' and are thus invisible to both patients and prescribers, yet are 'at high risk of being harmed' by GLP-1s. Given 10% lifetime ED prevalence and 43M+ Americans on GLP-1s, the theoretical overlap is enormous but completely unaddressed at the structural level. diff --git a/domains/health/glp1-pre-treatment-eating-disorder-screening-recommended-not-required.md b/domains/health/glp1-pre-treatment-eating-disorder-screening-recommended-not-required.md index 3dae8dc8e..925ab2f1e 100644 --- a/domains/health/glp1-pre-treatment-eating-disorder-screening-recommended-not-required.md +++ b/domains/health/glp1-pre-treatment-eating-disorder-screening-recommended-not-required.md @@ -31,3 +31,10 @@ Review explicitly states 'no definitive evidence of the causal relationship betw **Source:** VigiBase 2.06M reports, aROR analysis VigiBase analysis quantifies eating disorder signal magnitude at aROR 4.17-6.80 (4-7x higher reporting odds), the highest psychiatric signal in the study. However, database lacked pre-existing psychiatric condition data, preventing distinction between medicine-induced reactions and indication bias—supporting screening recommendation but not mandate. + + +## Supporting Evidence + +**Source:** NPR Health, Feb 2026 + +Article explicitly states 'no national guidelines requiring ED screening before prescription—only recommended by some professional groups.' This confirms the recommended-not-required status and documents the complete absence of regulatory enforcement. diff --git a/inbox/queue/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md b/inbox/archive/health/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md similarity index 97% rename from inbox/queue/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md rename to inbox/archive/health/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md index ddb0daed7..7f250680d 100644 --- a/inbox/queue/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md +++ b/inbox/archive/health/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md @@ -7,10 +7,13 @@ date: 2026-02-04 domain: health secondary_domains: [] format: article -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-05-04 priority: high tags: [glp1, eating-disorders, anorexia, atypical-anorexia, screening-gaps, access, misuse] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content